Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 324 participants.

Also called NCT06350123

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 324 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06350123
  • EU CT 2023-509709-63-00
Other papers using this trial's data
  • Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial Lancet (London, England), 2025-11-22 DOI, PubMed 41218621

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Brazil, Bulgaria, Canada, China, Italy, Japan, Malaysia, Poland, Spain, Taiwan, Türkiye, United Kingdom, Vietnam (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06350123. Randomized; quadruple masking; primary purpose treatment. Start 2024-05-01 (actual); primary completion 2025-05-09 (actual). Results posted on 2026-06-26.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
Acronym
MIRO-CKD
Intervention (Drug)
Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg
Intervention (Drug)
Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg
Intervention (Drug)
Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct06350123
Content hash
15174b5fd0ff776c6d10b76886432c48f81ee3b3776d5779c099a4edd0173aa3